Evidence map›Paper›PMID 39346679›Full record

ArticleTherapeutic advances in hematology2024

Prognostic impact of

Qiqi Tao, Qiaoyuan Wu, Yutong Xue, Changkun Chen, Ya Zhou, Ruoyang Shao, Haiyan Zhang, Hui Liu, Xiangzong Zeng, Lingling Zhou and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Therapeutic advances in hematology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Qiqi TaoDepartment of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou, China.
Qiaoyuan WuDepartment of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou, China.
Yutong XueDepartment of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou, China.
Changkun ChenDepartment of Hematology, Ganzhou Hospital-Nanfang Hospital, Southern Medical University, Ganzhou, Jiangxi, China.
Ya ZhouDepartment of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou, China.
Ruoyang ShaoDepartment of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou, China.
Haiyan ZhangDepartment of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou, China.
Hui Liu
Xiangzong ZengDepartment of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou, China.
Lingling ZhouDepartment of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou, China.
Qifa LiuDepartment of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou, China.
Hua JinDepartment of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China.ORCID https://orcid.org/0000-0001-9485-0249

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Interleukin-7 receptor ( Methods: A total of 346 newly diagnosed AML patients from January 2017 to July 2020 at Nanfang Hospital were analyzed in this study. A genomic panel of 167 gene targets was detected by next-generation sequencing. Results: Among 346 patients, 33 (9.5%) AML patients carried Conclusion: Our study demonstrated that the

Indexed as

acute myeloid leukemiahematopoietic stem cell transplantationIL7R mutationnext-generation sequencingprognosis analysis

Identifiers

PMID39346679
PMCPMC11439168

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.